Heparin‐Coated Circuits (Duraflo II) With Reduced Versus Full Anticoagulation During Coronary Artery Bypass Surgery

Abstract Background: Introduction of completely heparin‐coated cardiopulmonary bypass (CPB) circuits combined with reduced systemic anticoagulation has been shown to reduce postoperative bleeding and requirements for allogeneic transfusions after cardiac surgery. However, some uncertainty exists whether this effect is due to the reduced amount of heparin or to the heparinized surface itself. Therefore, a retrospective study was undertaken, comparing two different anticoagulation protocols applied to coronary artery bypass patients treated with identical heparin‐coated CPB equipment. Method: Over a 12 month period all coronary artery bypass patients operated with extracorporeal circulation were subjected to a Duraflo II heparin‐coated circuit (Baxter Healthcare Corp, Bentley Laboratories Division, Irvine, Calif) and full heparin dose (activated clotting time [ACT] > 480 seconds; Group F, n = 651). Over the next 24 months, all coronary patients who were treated with an identical circuit combined with reduced systemic heparinization (ACT > 250 seconds) were included in Group R(n = 675). Except for the different anticoagulation protocols, all treatment regimens before, during, and after the operation remained unchanged throughout the study period. Results: There were no statistically significant differences in any major demographic or operative parameters. In Group R, the postoperative bleeding was mean665 ± 257 mlversus757 ± 367 mlin Group F(p < 0.0001), and the perioperative decrease in hemoglobin concentration was significantly lower in Group R(22 ± 1.2 gm/L versus 25 ± 1.3 gm/L, p < 0.0001). The time for postoperative ventilatory support was shorter in Group R (1.7 ± 1.3 hours versus 1.9 ± 1.1 hours in Group F, p = 0.0006), and the incidence of new episodes of atrial fibrillation after the operation was lower (26.4% in Group R versus 32.8% in Group F,p = 0.01). There were no significant differences in the incidences of perioperative myocardial infarction, stroke, transient neurological disturbances, physical rehabilitation, or mortality. No technical or coagulation problems were recorded in either group. Conclusion: The use of Duraflo II coated circuits for CPB combined with reduced anticoagulation decrease postoperative bleeding and hemoglobin loss compared with full heparin dose treatment. In addition, the intubation time was shorter and the incidence of postoperative atrial fibrillation was lower in the patients treated with low heparin doses.(J Card Surg 2003;18:140‐146)

[1]  G. Tangen,et al.  Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations. , 2001, The Journal of thoracic and cardiovascular surgery.

[2]  T. Karlsson,et al.  Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[3]  G. Tangen,et al.  Autotransfusion in coronary artery bypass grafting: disparity in laboratory tests and clinical performance. , 1999, The Journal of thoracic and cardiovascular surgery.

[4]  A. Mazzucco,et al.  Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. , 1999, The Annals of thoracic surgery.

[5]  R. Shemin,et al.  Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. , 1998, The Annals of thoracic surgery.

[6]  T. Karlsson,et al.  Clinical effects of the heparin coated surface in cardiopulmonary bypass. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  D. Kuik,et al.  Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  G. Tangen,et al.  Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance. , 1996, The Annals of thoracic surgery.

[9]  R. Shemin,et al.  Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. , 1996, The Annals of thoracic surgery.

[10]  E. Øvrum Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass , 1996 .

[11]  E. Ovrum Eosinophil granulocyte activation and heparin-coated cardiopulmonary bypass. , 1996, Annals of Thoracic Surgery.

[12]  J. Maessen,et al.  Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass. , 1995, The Journal of thoracic and cardiovascular surgery.

[13]  E. Fosse,et al.  High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. , 1995, The Annals of thoracic surgery.

[14]  G. Tangen,et al.  Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. , 1995, Circulation.

[15]  J. Loscalzo,et al.  Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. , 1995, The Annals of thoracic surgery.

[16]  G. Tangen,et al.  Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. , 1995, The Annals of thoracic surgery.

[17]  G. Tangen,et al.  Consistent non-pharmacologic blood conservation in primary and reoperative coronary artery bypass grafting. , 1995, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[18]  E. Fosse,et al.  Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.

[19]  M. Pasic,et al.  Risk and benefit of low systemic heparinization during open heart operations. , 1994, The Annals of thoracic surgery.

[20]  J L Cox,et al.  Hazards of postoperative atrial arrhythmias. , 1994, The Annals of thoracic surgery.

[21]  W. van Oeveren,et al.  Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[22]  E. Fosse,et al.  Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. , 1992, The Journal of thoracic and cardiovascular surgery.

[23]  H. Macvaugh,et al.  Cardiovascular Effects of Protamine Sulfate in Man , 1981, Anesthesia and analgesia.